ISPOR EU 2025: What did we learn? Part 1/2

Many thanks to our clients and colleagues for supporting us during ISPOR 2025!

We had a great time in Glasgow. While we continue to value the efficiency of virtual meetings in our ongoing projects, this event reminded us how important face-to-face interactions still are. Thanks to everyone who stopped by!

One of the key takeaways in the RWE space

Despite technological progress and extensive data collection across registries, high-quality Real-World Data remain scarce — especially in oncology and rare diseases, and particularly when regulatory-grade data are required. With our OncoCase and PatientCase platforms, we are excited to help addressing this challenge. Their unique ability to automatically extract information from original patient charts, combined with an integrated patient mobile app, makes them ideal solutions for Medical Chart Reviews and prospective studies. We are also using OncoCase to build a unique German oncology dataset.

If you don’t want to wait until the next ISPOR to learn more, feel free to reach out to us!

info@gipam-health.com

Also interested in our second takeway? Look out for our next post!